Cosentyx (secukinumab)

pCPA File Number: 20951

Negotiation Status:

Concluded with an LOI

Indication(s):

Psoriatic Arthritis

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CDA-AMC Project Number:

SR0476-000

pCPA Engagement Letter Issued:

2017-04-13

Negotiation Process Concluded:

2017-12-19